Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0NHIIR |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | EDB-L19 |
|||||
| Organization | Pfizer Inc. |
|||||
| Synonyms |
EDB-L19
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized lgG |
|||||
| Antigen Name | Vesicle-associated membrane protein 8 (VAMP8) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
| Heavy Chain Sequence |
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFSMSWVRQAPGKGLEWVSSISGSSGTTYY
ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPFPYFDYWGQGTLVTVSSASTK GPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVF LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGK Click to Show/Hide
|
|||||
| Heavy Chain Varible Domain |
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFSMSWVRQAPGKGLEWVSSISGSSGTTYY
ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPFPYFDYWGQGTLVTVSS Click to Show/Hide
|
|||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
EDB-L19-diS-C2OCO-1569 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
5 ng/mL
|
Negative EDB expression (EDB-) | ||
| Method Description |
Calculated using four-parameter logistic model #203 with XLfit v4.4 (IDBS)
|
||||
| In Vitro Model | Colon cancer | HT29 cells | CVCL_A8EZ | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
21 ng/mL
|
Positive EDB expression (EDB+++/++) | ||
| Method Description |
Calculated using four-parameter logistic model #203 with XLfit v4.3 (IDBS)
|
||||
| In Vitro Model | Normal | WI38-VA13 cells | CVCL_2759 | ||
EDB-L19-vc-1569 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
40 ng/mL
|
Positive EDB expression (EDB+++/++) | ||
| Method Description |
Calculated using four-parameter logistic model #203 with XLfit v4.11 (IDBS)
|
||||
| In Vitro Model | Normal | WI38-VA13 cells | CVCL_2759 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
5702 ng/mL
|
Negative EDB expression (EDB-) | ||
| Method Description |
Calculated using four-parameter logistic model #203 with XLfit v4.12 (IDBS)
|
||||
| In Vitro Model | Colon cancer | HT29 cells | CVCL_A8EZ | ||
EDB-L19-vc-9411 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
46 ng/mL
|
Positive EDB expression (EDB+++/++) | ||
| Method Description |
Calculated using four-parameter logistic model #203 with XLfit v4.5 (IDBS)
|
||||
| In Vitro Model | Normal | WI38-VA13 cells | CVCL_2759 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
1153 ng/mL
|
Negative EDB expression (EDB-) | ||
| Method Description |
Calculated using four-parameter logistic model #203 with XLfit v4.6 (IDBS)
|
||||
| In Vitro Model | Colon cancer | HT29 cells | CVCL_A8EZ | ||
EDB-L19-vc-0101 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
184 ng/mL
|
Positive EDB expression (EDB+++/++) | ||
| Method Description |
Calculated using four-parameter logistic model #203 with XLfit v4.2 (IDBS)
|
||||
| In Vitro Model | Normal | WI38-VA13 cells | CVCL_2759 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
15346 ng/mL
|
Negative EDB expression (EDB-) | ||
| Method Description |
Calculated using four-parameter logistic model #203 with XLfit v4.2 (IDBS)
|
||||
| In Vitro Model | Colon cancer | HT29 cells | CVCL_A8EZ | ||
EDB-L19-diS-DM1 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
237 ng/mL
|
Negative EDB expression (EDB-) | ||
| Method Description |
Calculated using four-parameter logistic model #203 with XLfit v4.2 (IDBS)
|
||||
| In Vitro Model | Colon cancer | HT29 cells | CVCL_A8EZ | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
268 ng/mL
|
Positive EDB expression (EDB+++/++) | ||
| Method Description |
Calculated using four-parameter logistic model #203 with XLfit v4.2 (IDBS)
|
||||
| In Vitro Model | Normal | WI38-VA13 cells | CVCL_2759 | ||